Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.

Journal for Immunotherapy of Cancer
Monika GraeserNadia Harbeck

Abstract

The association of early changes in the immune infiltrate during neoadjuvant chemotherapy (NACT) with pathological complete response (pCR) in triple-negative breast cancer (TNBC) remains unexplored. Multiplexed immunohistochemistry was performed in matched tumor biopsies obtained at baseline and after 3 weeks of NACT from 66 patients from the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer (WSG-ADAPT-TN) trial. Association between CD4, CD8, CD73, T cells, PD1-positive CD4 and CD8 cells, and PDL1 levels in stroma and/or tumor at baseline, week 3 and 3-week change with pCR was evaluated with univariable logistic regression. Compared with no change in immune cell composition and functional markers, transition from 'cold' to 'hot' (below-median and above-median marker level at baseline, respectively) suggested higher pCR rates for PD1-positive CD4 (tumor: OR=1.55, 95% CI 0.45 to 5.42; stroma: OR=2.65, 95% CI 0.65 to 10.71) and PD1-positive CD8 infiltrates (tumor: OR=1.77, 95% CI 0.60 to 5.20; stroma: OR=1.25, 95% CI 0.41 to 3.84; tumor+stroma: OR=1.62, 95% CI 0.51 to 5.12). No pCR was...Continue Reading

References

Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jul 7, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nehmat HoussamiEleftherios Mamounas
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew D BursteinPowel H Brown
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertSibylle Loibl
Oct 31, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sherene LoiJustin M Balko
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Aug 30, 2017·Histopathology·Andreas H ScheelJosef Rüschoff
Oct 21, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Reinhard BüttnerMing-Sound Tsao
Feb 3, 2018·Cancer Management and Research·Claudia OmariniFederico Piacentini
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Jan 6, 2019·Nature Reviews. Drug Discovery·Jérôme Galon, Daniela Bruni
Dec 20, 2019·Virchows Archiv : an International Journal of Pathology·Bruna CerbelliGiulia d'Amati
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J H ParkS Michiels
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre
Feb 27, 2020·The New England Journal of Medicine·Peter SchmidUNKNOWN KEYNOTE-522 Investigators
Apr 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Tanya E Keenan, Sara M Tolaney
Feb 13, 2021·NPJ Breast Cancer·Mohamed AmgadUNKNOWN International Immuno-Oncology Biomarker Working Group

❮ Previous
Next ❯

Software Mentioned

Image Miner
inForm Advanced Image Analysis
STATA SE
inForm

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.